NCT01203371View on ClinicalTrials.gov

Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 1, 2011

Primary Completion Date

September 1, 2011

Study Completion Date

January 1, 2012

Conditions
Hyperplasia
Interventions
DRUG

Naftopidil

0,25 mg (2weeks) and 0,50 mg (10 weeks)

DRUG

Tamsulosin

0,4 mg/day

Trial Locations (1)

05403-010

Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo

Sponsors
All Listed Sponsors
lead

Apsen Farmaceutica S.A.

INDUSTRY

NCT01203371 - Efficacy And Safety Study Of Naftopidil to Patients Treatment With LUTS | Biotech Hunter | Biotech Hunter